Company intelligence / Profile preview
Vion Pharmaceuticals
New Haven, Connecticut, United Statesvionpharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company developed small molecule oncology drugs, most notably laromustine (VNP40101M), a sulfonylhydrazine alkylating agent. Clinical trials included combinations with cytarabine for AML and MDS, but the company ceased operations following bankruptcy and delisting from Nasdaq in August 2008. No products reached commercialization.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Vion Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vion Pharmaceuticals.